ALGENSCRIBE
LIVE

Serial Number

79374320

Owner

ALGENSCRIBE

Attorney

Cathleen E. Stadecker

Filing Date

Apr 7, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ALGENSCRIBE Trademark

Serial Number: 79374320 • Registration: 7424131

ALGENSCRIBE is a trademark filed by ALGENSCRIBE on April 7, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

ALGENSCRIBE

61-63 avenue Simone Veil

Entity Type: 34

Trademark Details

Filing Date

April 7, 2023

Registration Date

June 25, 2024

Published for Opposition

April 9, 2024

Goods & Services

Chemical, biochemical, biotechnological products intended for use in industry, science, agriculture, horticulture, namely, chemical and biochemical preparations for scientific purposes, chemicals for use in biotechnological product development, chemicals and biochemicals used in industry; Chemical, biochemical, biotechnological and bacteriological products for use in research and testing laboratories, namely, chemical and biochemical preparations for research purposes, chemicals for use in biotechnological product development, other than for medical or veterinary purposes; Chemical and biochemical preparations used in the manufacture of pharmaceuticals; Biotechnological products used in the manufacture of pharmaceuticals, namely, chemicals for use in biotechnological product development; Chemical preparations used for the production of gene and cell therapies; Diagnostic preparations other than for medical use; Diagnostic reagents and preparations for scientific use; Diagnostic reagents and preparations for scientific laboratories; Reagents for analytical use, namely, chemical analysis reagents other than for medical or veterinary purposes; Reagents for the extraction, preservation and processing of human, animal, plant or microbiological samples for collecting genetic or genomic information other than for medical or veterinary purposes; Diagnostic testing preparations, namely, reagents and assays for scientific use

Medical diagnostic services, including diagnostic and reagent sample testing services for third parties; Genetic testing for medical purposes, including genome mapping, genome analysis and genome scanning; Biological, genetic and genomic handling and analysis services for medical use; Medical genetic or genomic testing for detecting risks, diagnosing illness or selecting treatment in humans, animals or plants

Veterinary and pharmaceutical preparations, namely, gene-based and cell-based therapeutic preparations for treating cancer; Pharmaceutical preparations for gene and cell therapy; Biological preparations for use in gene therapy and cell therapy for medical purposes; Micro-organism cultures and preparations for medical, pharmaceutical and/or veterinary use; Bacteriological preparations for medical, pharmaceutical and/or veterinary use; Diagnostic reagents and preparations for clinical, medical, pharmaceutical and/or veterinary use; Diagnostic test preparations consisting principally of reagents and assays for clinical, medical, pharmaceutical and/or veterinary use

Scientific and industrial research, namely, chemical research, research and development of new biological and medical products; Scientific genetic, medical, pharmaceutical and veterinary research; Scientific genetic, medical, pharmaceutical and veterinary research, namely, research in the field of pharmaceutical preparations for gene and cell therapy; Research in chemistry, biology, biochemistry, molecular biology; Scientific research in the field of biology, genetics and genomics; Scientific research services using genomic analysis procedures; Biological, scientific genetic and genomic handling and analysis services for scientific use; Structural and functional genome analysis, for scientific purposes; Biotechnological research and development for third parties, including scientific feasibility studies on genetic associations, genome mapping, genome analysis and genome scanning; Scientific analysis in the field of genetics and genomics; Scientific research and development of biochemical analysis, biological analysis and molecular biology techniques; Research and development of new molecules intended for use in industry, preparing and providing biological materials and particularly stem cells; Developing pharmaceutical drugs and therapeutics; Scientific laboratory services, namely, biological material modifications

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 1, 2025 FINO
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 21, 2025 OPNX
FINAL DISPOSITION NOTICE SENT TO IB
Feb 13, 2025 FICS
FINAL DISPOSITION PROCESSED
Feb 13, 2025 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 24, 2025 OPNS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 24, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 24, 2025 OPNR
NEW REPRESENTATIVE AT IB RECEIVED
Jan 23, 2025 NREP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 25, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 25, 2024 R.PR
NOTIFICATION PROCESSED BY IB
Apr 16, 2024 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 9, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 9, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 27, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 27, 2024 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 20, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 6, 2024 CNSA
REFUSAL PROCESSED BY IB
Feb 19, 2024 RFNT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 13, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 13, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 13, 2024 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 29, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jan 29, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 12, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jan 11, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 4, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 21, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 17, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 13, 2023 REPR